Abiomed announces first commercial AbioCor artificial heart implantation
June 24, 2009 by MassDevice staff
A 76-year-old man is the first patient implanted with the Danvers cardiac device maker's artificial heart since it won FDA approval in 2006.
A 76-year-old patient in New Jersey is said to be recovering well after receiving Abiomed Inc.'s AbioCor artificial heart.
It's the first commercial implantation since the Danvers cardiac device maker's artificial heart went through clinical trials and won humanitarian device exemption approval from the Food and Drug Administration in 2006.
The device, which made headlines early this decade as the first self-contined artificial heart, is designed for patient with acute heart failure who don't qualify for a transplant.
- Show full page
- Login to post comments
-
Permalink
FDA Database Search
RECENT BLOG POSTS
- Funding R&D: High prices, overuse a failed strategy
- FDA's role in promoting women's health
- New partnership to boost use of GMDN codes for medical devices
- FDA's modern "Corps of Discovery" in China
- Consumers lose in latest FDA user fee bill; COI restraints disappear
- Gamification
- Cool technology of the week
- A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
- When a child loses milestones, consider sleep EEG studies
- Red or blue pill for payment reform? Both won't work
NEWS
MassDevice.com +3 | The top 3 med-tech stories for May 15, 2012.
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on...
Electromed CEO Robert Hansen retires after 20 years at the helm | Personnel Moves
Electromed founder, chairman & CEO Robert Hansen announces his retirement after 20 years leading...
St. Jude Medical gains on Goldman upgrade | Wall Street Beat
St. Jude Medical's shares get a 2% lift from an upgrade by a Goldman Sachs analyst.
SEC closed probe of Zoll's Middle East sales just ahead of $2.3B Asahi merger
Just weeks before a $2.3 billion acquisition by Asahi Kasei closed, the Securities & Exchange...
Boston Scientific's Synergy bioabsorbable stent stands up to Promus Element
Boston Scientific's Synergy bioabsorbable drug-eluting stent proves just as good as its leading and...
